mGluR5 Negative Modulators for Fragile X: Treatment Resistance and Persistence
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is caused by silencing of the human FMR1 gene and is the leading monogenic cause of intellectual disability and autism. Abundant preclinical data indicated that negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGluR5) might be efficacious in treating FXS in humans. Initial attempts to translate these findings in clinical trials have failed, but these failures provide the opportunity for new discoveries that will improve future trials. The emergence of acquired treatment resistance (“tolerance”) after chronic administration of mGluR5 NAMs is a potential factor in the lack of success. Here we confirm that FXS model mice display acquired treatment resistance after chronic treatment with the mGluR5 NAM CTEP in three assays commonly examined in the mouse model of FXS: (1) audiogenic seizure susceptibility, (2) sensory cortex hyperexcitability, and (3) hippocampal protein synthesis. Cross-tolerance experiments suggest that the mechanism of treatment resistance likely occurs at signaling nodes downstream of glycogen synthase kinase 3α (GSK3α), but upstream of protein synthesis. The rapid emergence of tolerance to CTEP begs the question of how previous studies showed an improvement in inhibitory avoidance (IA) cognitive performance after chronic treatment. We show here that this observation was likely explained by timely inhibition of mGluR5 during a critical period, as brief CTEP treatment in juvenile mice is sufficient to provide a persistent improvement of IA behavior measured many weeks later. These data will be important to consider when designing future fragile X clinical trials using compounds that target the mGluR5-to-protein synthesis signaling cascade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“This line of reasoning provided the rationale behind the “mGluR theory of fragile X,” as metabotropic glutamate receptor 5 (mGluR5) is widely expressed in the forebrain and known to modulate neuronal protein synthesis (22, 23).”
BackgroundSelf-citationAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 1×
“This line of reasoning provided the rationale behind the “mGluR theory of fragile X,” as metabotropic glutamate receptor 5 (mGluR5) is widely expressed in the forebrain and known to modulate neuronal protein synthesis (22, 23).”
BackgroundSelf-citationCorrection of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979 · cited 1×
“An elevated rate of basal protein synthesis in the hippocampus of Fmr1-KO mice and rats is a hallmark fragile X phenotype, and it is rescued by inhibiting proteins in the signaling cascade linking mGluR5 activation with protein synthesis [5; 12; 32; 33; 41; 42; 43; 44; 45].”
BackgroundSelf-citationSuppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521 · cited 5×
“There was a statistically significant effect of genotype [two-way ANOVA, F (1,30) = 15.”
BackgroundMethodResultInfluentialChronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Self-citationThe Pathophysiology of Fragile X Syndrome
Penagarikano, O., Mulle, J. G., & Warren, S. T. (2007) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.8.080706.092249 · Cited by 420 · cited 7×
“sensory cortex hyperexcitability, and (3) hippocampal protein synthesis.”
BackgroundInfluentialOsterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384 · cited 2×
“One feature that these fragile X phenotypes have in common, however, is that they have been shown to be corrected rapidly (within tens of minutes) by acute inhibition of mGluR5 signaling in drug naïve animals (12, 30, 33).”
BackgroundMethodSelf-citationThe Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370 · cited 1×
“Indeed, extensive studies in multiple animal models of FXS have shown that diverse disease phenotypes are corrected by inhibiting mGluR5 or key signaling nodes downstream of this receptor (8, 24, 25).”
BackgroundSelf-citationDeng, P.-Y., Rotman, Z., Blundon, J. A., Cho, Y., Cui, J., Cavalli, V., Zakharenko, S. S., & Klyachko, V. A. (2013) · Neuron · doi:10.1016/j.neuron.2012.12.018 · Cited by 354
Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome
Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.221 · Cited by 336
Self-citationDysregulation and restoration of translational homeostasis in fragile X syndrome
Richter, J. D., Bassell, G. J., & Klann, E. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4001 · Cited by 275 · cited 1×
“…related to two well described neuronal functions of FMRP: (1) altered protein synthesis regulation caused by loss of FMRP binding to mRNA [5; 6; 7; 8; 9; 10; 11; 12; 13], and (2) altered ion channel function caused by the disruption of FMRP protein-protein interactions with ion channels [9;…”
BackgroundBerry-Kravis, E., Des Portes, V., Hagerman, R., Jacquemont, S., Charles, P., Visootsak, J., Brinkman, M., Rerat, K., Koumaras, B., Zhu, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aab4109 · Cited by 270 · cited 2×
“However, these studies failed to demonstrate improvements in the primary therapeutic endpoints [26].”
Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome
Ronesi, J. A., Collins, K. A., Hays, S. A., Tsai, N.-P., Guo, W., Birnbaum, S. G., Hu, J.-H., Worley, P. F., Gibson, J. R., & Huber, K. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3033 · Cited by 251 · cited 2×
“…to two well described neuronal functions of FMRP: (1) altered protein synthesis regulation caused by loss of FMRP binding to mRNA [5; 6; 7; 8; 9; 10; 11; 12; 13], and (2) altered ion channel function caused by the disruption of FMRP protein-protein interactions with ion channels [9; 14; 15;…”
BackgroundOsterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230 · cited 3×
“One feature that these fragile X phenotypes have in common, however, is that they have been shown to be corrected rapidly (within tens of minutes) by acute inhibition of mGluR5 signaling in drug naïve animals (12, 30, 33).”
BackgroundSelf-citationGkogkas, C. G., Khoutorsky, A., Cao, R., Jafarnejad, S. M., Prager-Khoutorsky, M., Giannakas, N., Kaminari, A., Fragkouli, A., Nader, K., Price, T. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.064 · Cited by 201 · cited 1×
“An elevated rate of basal protein synthesis in the hippocampus of Fmr1-KO mice and rats is a hallmark fragile X phenotype, and it is rescued by inhibiting proteins in the signaling cascade linking mGluR5 activation with protein synthesis [5; 12; 32; 33; 41; 42; 43; 44; 45].”
BackgroundStrumbos, J. G., Brown, M. R., Kronengold, J., Polley, D. B., & Kaczmarek, L. K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1125-10.2010 · Cited by 135 · cited 1×
“…described neuronal functions of FMRP: (1) altered protein synthesis regulation caused by loss of FMRP binding to mRNA [5; 6; 7; 8; 9; 10; 11; 12; 13], and (2) altered ion channel function caused by the disruption of FMRP protein-protein interactions with ion channels [9; 14; 15; 16; 17; 18; 19].”
BackgroundAsiminas, A., Jackson, A. D., Louros, S. R., Till, S. M., Spano, T., Dando, O., Bear, M. F., Chattarji, S., Hardingham, G. E., Osterweil, E. K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0498 · Cited by 78
Self-citation
Cited by
Hyperexcitability and homeostasis in fragile X Syndrome.
Liu, X., Kumar, V., Tsai, N.-P., & Auerbach, B. D. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.805929 · Cited by 53
Janz, P., Bainier, M., Marashli, S., Gross, S., & Redondo, R. L. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110182 · Cited by 11
“…protein synthesis, short-term plasticity deficits, audiogenic seizures, neuronal hyperexcitability and audiogenic seizures (Michalon et al., 2012; Stoppel et al., 2021), as well as abnormal open field behavior (Yan et al., 2005), prepulse inhibition deficits and elevated spine density in vitro…”
BackgroundAstrocytes in fragile X syndrome
Talvio, K., & Castrén, M. L. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1322541 · Cited by 8
Metadata
- Authors
- Stoppel, D. C., McCamphill, P. K., Senter, R. K., Heynen, A. J., & Bear, M. F.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2021-09-29
- Volume
- 12
- Pages
- 718953-718953
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W3201949744
- Cited by
- 40
- References
- 17
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.